Understanding Eczema

Eczema (dermatitis) encompasses multiple pruritic, inflammatory skin conditions. Atopic dermatitis (AD) is the most common form, affecting 10-20% of children and 1-3% of adults. Characterized by intense pruritus, lichenification from chronic scratching, and significant quality-of-life impact. The itch-scratch cycle perpetuates inflammation and barrier dysfunction. Unlike other skin conditions, eczema represents dysfunction in multiple systems: structural barrier, immune response, and sensory perception.

Types of Eczema

Atopic Dermatitis

Most common form; often begins in infancy or childhood (80% by age 5), though adult-onset occurs. Associated with elevated IgE levels, eosinophilia, and family history of atopy (asthma, allergic rhinitis, atopic dermatitis). Presents with lichenified plaques, often on flexural surfaces (antecubital and popliteal fossae). Pruritus is often worse at night and with stress.

Contact Dermatitis

Allergic contact dermatitis results from delayed-type hypersensitivity to specific allergens (nickel, fragrances, preservatives). Irritant contact dermatitis results from irritant exposure without immune sensitivity. Both present with erythema, edema, vesicles, and pruritus at contact sites.

Dyshidrotic Eczema

Presents with clusters of small vesicles on palms and soles, intensely pruritic. Often associated with stress, seasonal factors, and nickel sensitivity. High recurrence rate.

Seborrheic Dermatitis

Affects areas with high sebaceous gland concentration (scalp, face, upper trunk). Associated with Malassezia fungus and altered immune response. Presents with erythema and greasy scale.

Disease Mechanisms

Atopic dermatitis involves genetic predisposition (filaggrin mutations reduce barrier function by 30%), impaired innate immune response (altered toll-like receptor signaling), Th2-skewed adaptive immunity (increased IL-4, IL-5, IL-13), barrier dysfunction (reduced ceramides, altered lipid composition), and dysbiosis (altered skin microbiome with increased Staphylococcus aureus colonization). The interplay of genetic predisposition and environmental triggers creates chronic inflammation.

Identifying Triggers

Irritants: Soaps, detergents, fragrances, and dyes strip natural oils and disrupt barrier. Over-washing exacerbates disease. Allergens: Nickel jewelry, latex, fragrance ingredients, preservatives, and lanolin cause allergic contact dermatitis. Microbes: Staphylococcus aureus colonization increases disease severity; infections trigger flares. Stress: Psychological stress exacerbates 40-60% of cases through neuro-immune mechanisms. Climate: Low humidity, cold temperatures worsen disease; heat and sweating may trigger flares. Clothing: Wool and synthetic fabrics irritate; cotton is preferred.

Skin Barrier Dysfunction

The epidermis functions as a barrier through tight junctions and lipid-rich stratum corneum. Eczema reduces ceramides, free fatty acids, and cholesterol, impairing barrier function. Increased transepidermal water loss (TEWL) causes dryness. Irritant and allergen penetration increases. Repair requires topical lipid replacement; ceramide-containing products support barrier restoration. Intensive moisturization during active disease and twice-daily during maintenance prevents flares.

Management Strategy

Step-wise approach: (1) Aggressive hydration and barrier repair with ceramide-containing moisturizers applied to damp skin; (2) Trigger identification and avoidance; (3) Topical corticosteroids or calcineurin inhibitors for active inflammation; (4) Phototherapy for moderate-to-severe disease; (5) Systemic agents (dupilumab, cyclosporine, JAK inhibitors) for severe disease refractory to topical therapy. Regular reassessment guides step-down as disease improves.

Treatment Options

Moisturization

Foundation of eczema management. Ceramide-containing products (CeraVe, Aveeno Eczema Therapy) repair barrier. Apply within 3 minutes of bathing to lock in moisture. Occlusive products (petrolatum, dimethicone) provide additional protection for severe flares.

Topical Anti-Inflammatories

Corticosteroids reduce inflammation rapidly; select potency based on location and severity. Proactive therapy (twice-weekly application to previously affected areas) prevents flares. Calcineurin inhibitors (tacrolimus, pimecrolimus) are steroid-sparing, safe for face and skin folds, without atrophy risk.

Phototherapy

NB-UVB (twice-weekly) effectively treats moderate-to-severe disease with sustained remission in 70% of patients. Safe for children and pregnant women. Requires 8-12 weeks initial commitment.

Systemic Therapy

Dupilumab (anti-IL-4 receptor) provides rapid improvement and sustained remission in 60-70% of severe AD patients, with FDA approval for both adult and pediatric use. Cyclosporine provides rapid control suitable for flares. JAK inhibitors (upadacitinib, baricitinib) represent newer options with favorable safety profiles.

Expert Tip

Barrier repair is often overlooked in favor of topical medications, yet intensive moisturization alone controls mild eczema and significantly reduces flare frequency and severity in all disease levels. Patients applying moisturizer 2+ times daily typically require less medication.

Lifestyle Modifications

  • Bathe or shower in lukewarm (not hot) water for 5-10 minutes
  • Use fragrance-free, hypoallergenic cleansers; avoid soap
  • Apply moisturizer within 3 minutes of bathing while skin is damp
  • Wear soft, breathable fabrics (100% cotton preferred)
  • Avoid fragranced products, including perfumed detergents and fabric softeners
  • Identify and avoid personal triggers through journaling
  • Manage stress through exercise, meditation, or counseling
  • Maintain indoor humidity 30-50% to prevent environmental dryness
  • Consider allergy testing if contact allergies suspected